| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM |
Revenue  | 147 | 129 | 125 | 36 | 88 | 68 | 87 | 80 | 47 | 9 |
| Expenses | 143 | 133 | 112 | 43 | 93 | 77 | 106 | 83 | 63 | 25 |
| EBITDA | 4 | -4 | 14 | -7 | -5 | -9 | -19 | -4 | -16 | -17 |
| Operating Profit % | 2 % | -4 % | 10 % | -24 % | -11 % | -16 % | -24 % | -6 % | -41 % | -13 % |
| Depreciation | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 5 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Profit Before Tax | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
| Tax | 1 | -3 | 3 | -4 | -2 | -4 | -6 | -1 | -6 | 0 |
| Net Profit | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| EPS in ₹ | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | 1.10 | -2.03 | -3.95 | -4.20 |
Bharat Immunologicals
Bharat Immunologicals
23.14
+0.57
(2.53%)
Market Cap
99.96 Cr
EPS
-3.95
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
35.88
52 Week Low
19.00
PB Ratio
-3.00
Debt to Equity
0.00
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,642.00 | #1 3,93,970.80 | 34.30 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 47.35 | |
6,088.00 | 1,61,617.27 | 69.37 | 9,712.00 | 18.67 | 2,191 | 26.74 | 35.29 | |
1,590.00 | 1,28,425.54 | 23.86 | 28,409.50 | 7.12 | 5,291 | 9.88 | 66.07 | |
3,643.00 | 1,23,295.67 | 61.13 | 11,539.40 | 6.99 | 1,911 | 19.91 | 59.05 | |
2,588.00 | 1,06,814.20 | 56.78 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 60.15 | |
1,274.10 | 1,06,332.70 | #1 18.75 | 33,741.20 | 16.73 | 5,725 | 1.26 | 57.30 | |
992.00 | 99,818.41 | 21.29 | 23,511.00 | 18.55 | 4,615 | 2.60 | 56.17 | |
1,970.00 | 89,969.01 | 24.22 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 53.40 | |
32,745.00 | 69,580.84 | 47.71 | 6,684.70 | 9.64 | 1,414 | 11.55 | 44.46 | |
5,470.00 | 65,402.06 | 28.51 | 13,458.30 | 3.70 | 2,216 | 21.39 | 70.65 |
Forecast
Actual
Growth Rate
Revenue Growth
-40.38 %
Net Income Growth
94.32 %
Cash Flow Change
125.85 %
ROE
133.81 %
ROCE
357.22 %
EBITDA Margin (Avg.)
577.05 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| Total Assets | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 |
| Fixed Assets | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 116 | 115 |
| Current Assets | 74 | 60 | 47 | 38 | 99 | 93 | 34 | 65 | 33 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 |
| Total Liabilities | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 |
| Current Liabilities | 35 | 30 | 14 | 13 | 89 | 101 | 64 | 101 | 91 |
| Non Current Liabilities | 4 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 6 |
| Total Equity | 41 | 35 | 42 | 38 | 31 | 21 | 34 | 105 | 88 |
| Reserve & Surplus | -2 | -8 | -1 | -6 | -13 | -23 | -9 | 62 | 45 |
| Share Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| Net Cash Flow | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
| Investing Activities | 0 | 1 | 1 | -1 | 1 | 1 | 1 | 1 | 1 |
| Operating Activities | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| Financing Activities | -1 | -2 | -3 | -1 | 31 | -34 | -12 | 45 | -15 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 |
| Promoter | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % | 59.25 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 37.32 % | 37.50 % | 38.51 % | 39.58 % | 38.77 % | 39.15 % | 39.11 % | 38.86 % | 38.97 % | 39.13 % | 39.30 % | 39.35 % | 39.47 % |
| Others | 3.43 % | 3.25 % | 2.24 % | 1.17 % | 1.97 % | 1.59 % | 1.63 % | 1.88 % | 1.77 % | 1.61 % | 1.45 % | 1.39 % | 1.28 % |
| No of Share Holders | 33,938 | 38,195 | 36,799 | 36,869 | 36,323 | 35,695 | 35,411 | 36,242 | 35,535 | 34,818 | 34,201 | 34,910 | 35,313 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Dec 2023 |  Annual General Meeting | NA | 29 Dec 2023 | 25.89 | 36.14 |
Announcements
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR.
Aug 07, 2024
Aug 07, 2024Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR.Feb 29, 2024
Feb 29, 2024Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023.Dec 13, 2023
Dec 13, 2023Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (22.12.2023 To 29.12.2023) Of The Company In Respect Of 34Th Annual General Meeting Scheduled To Be Held On 29.12.2023.Nov 28, 2023
Nov 28, 2023Submission Of Notice Of 34Th Annual General Meeting On 29.12.2023 As Compliance Of The Provision Of LODR 2015.Nov 28, 2023
Nov 28, 2023Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter And Half Year Ended September 2023 As Compliance Of LODR 2015Nov 01, 2023
Nov 01, 2023Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter Ended June 2023 As Compliance Of LODR 2015Nov 01, 2023
Nov 01, 2023Board Meeting Intimation for Intimation Of Date Of Board Meeting On 31St October 2023 Under Regulation 29 Of SEBI'S LODR.Oct 19, 2023
Oct 19, 2023Submission Of Signed Audited Annual Accounts 2022-23 Alongwith Statutory Audit Report Thereof Provided By The Statutory Auditor Appointed By Comptroller & Auditor General Of India (C&AG).Sep 15, 2023
Sep 15, 2023Submission Of Annual Accounts For The Financial Year Ended On 31.03.2023 And Is Under Audit Of Statutory Auditor Appointed By C&AGMay 31, 2023
May 31, 2023Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 10, 2023
May 10, 2023Compliance Certificate Under Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ending On 31.03.2023.May 10, 2023
May 10, 2023Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2023Apr 27, 2023
Apr 27, 2023Update on board meetingApr 17, 2023
Apr 17, 2023Board Meeting Intimation for Intimation Of Date Of Board Meeting On 17Th April 2023 Under Regulation 29 Of SEBI'S LODR.Apr 17, 2023
Apr 17, 2023Submission Of Unaudited Quarterly Financial Results For The Quarter And Nine Months Ended December 2022 Along With Limited Review ReportFeb 10, 2023
Feb 10, 2023Board Meeting Intimation for Intimation Of Date Of Board Meeting On 09Th February 2023 Under Regulation 29 Of SEBI'S LODR.Feb 01, 2023
Feb 01, 2023Clarification sought from Bharat Immunologicals & Biologicals Corporation LtdDec 27, 2022
Dec 27, 2022Board Meeting Outcome for Submission Of Un-Audited Quarterly Financial Results For The Quarter Ended September 2022 And Limited Review Report Thereon As Per The Compliance Of LODR 2015Oct 17, 2022
Oct 17, 2022Statement Of Investor Complaints For The Quarter Ended September 2022Oct 11, 2022
Oct 11, 2022Board Meeting Intimation for Intimation Of Date Of Board Meeting On 17Th October 2022Oct 06, 2022
Oct 06, 2022Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI LODR 2015 For The Year 2021-22.Sep 29, 2022
Sep 29, 2022Reg. 34 (1) Annual Report.Sep 23, 2022
Sep 23, 2022Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (23.09.2022 To 30.09.2022) Of The Company In Respect Of 33Rd Annual General Meeting Scheduled To Be Held On 30.09.2022.Sep 06, 2022
Sep 06, 2022Submission Of Notice Of 33Rd Annual General Meeting On 30.09.2022 As Compliance Of The Provision Of LODR 2015.Sep 06, 2022
Sep 06, 2022Board Meeting Outcome for Submission Of Un-Audited Quarterly Financial Results For The Quarter Ended June 2022 And Limited Review Report Thereon As Per The Compliance Of LODR 2015Aug 15, 2022
Aug 15, 2022Board Meeting Intimation for Intimation Of Date Of Board Meeting On 11Th August 2022 Under Regulation 29 Of SEBI'S LODR.Aug 03, 2022
Aug 03, 2022Compliances-Reg.24(A)-Annual Secretarial ComplianceJul 13, 2022
Jul 13, 2022Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2022Jun 15, 2022
Jun 15, 2022Submission Of Reviewed Annual Financial Results For The Year Ended 31.03.2022May 31, 2022
May 31, 2022Board Meeting Intimation for Intimation Of Date Of Board Meeting On 30Th May 2022 Under Regulation 29 Of SEBI'S LODR.May 18, 2022
May 18, 2022Statement Of Investor Complaints For The Quarter Ended March 2022Apr 08, 2022
Apr 08, 2022Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended December 2021 Under Regulation 33(3)(C ) Of LODRFeb 09, 2022
Feb 09, 2022Board Meeting Outcome for Submission Of Unaudited Quarterly Financial Results For The Quarter Ended December 2021 As Compliance Of LODR 2015Feb 09, 2022
Feb 09, 2022Board Meeting Intimation for Intimation Of Date Of Board Meeting On 8Th February 2022 Under Regulation 29 Of SEBI'S LODRJan 31, 2022
Jan 31, 2022Shareholding for the Period Ended December 31, 2021Jan 31, 2022
Jan 31, 2022Statement Of Investor Complaints For The Quarter Ended December 2021Jan 10, 2022
Jan 10, 2022Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)Dec 01, 2021
Dec 01, 2021Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR, Related Party Transaction - NILNov 15, 2021
Nov 15, 2021Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODRNov 15, 2021
Nov 15, 2021Reg. 34 (1) Annual ReportNov 08, 2021
Nov 08, 2021Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (23.11.2021 To 30.11.2021) Of The Company In Respect Of 32Nd Annual General Meeting Scheduled To Be Held On 30.11.2021.Nov 01, 2021
Nov 01, 2021Submission Of Notice Of 32Nd Annual General Meeting On 30.11.2021 As Compliance Of The Provision Of LODR 2015Nov 01, 2021
Nov 01, 2021Board Meeting Outcome for Submission Of Unaudited Quarterly Financial Results For The Quarter And Half Year Ended September 2021 As Compliance Of LODR 2015Oct 30, 2021
Oct 30, 2021Board Meeting Intimation for Intimation Of Date Of Board Meeting On 29Th October 2021 Under Regulation 29 Of SEBI'S LODR.Oct 22, 2021
Oct 22, 2021Shareholding for the Period Ended September 30, 2021Oct 19, 2021
Oct 19, 2021Statement Of Investor Complaints For The Quarter Ended September 2021Oct 11, 2021
Oct 11, 2021Submission Of Limited Review Report On Unaudited Quarterly Financial Results For Quarter Ended June 2021In Compliance Of SEBI LODR Please.Aug 15, 2021
Aug 15, 2021Compliances-Reg.24(A)-Annual Secretarial ComplianceAug 01, 2021
Aug 01, 2021Submission Of Unaudited Quarterly Financial Results For The Quarter Ended June 2021 As Compliance Of LODR 2015.<BR>Jul 27, 2021
Jul 27, 2021Technical Indicators
RSI(14)
Neutral 52.54
ATR(14)
Less Volatile 0.90
STOCH(9,6)
Neutral 64.32
STOCH RSI(14)
Overbought 94.34
MACD(12,26)
Bullish 0.16
ADX(14)
Strong Trend 33.81
UO(9)
Bearish 48.63
ROC(12)
Uptrend And Accelerating 3.01
WillR(14)
Neutral -26.50
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
